Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Surufatinib - HUTCHMED

Next Previous
Drug Profile

Surufatinib - HUTCHMED

Alternative Names: HMPL-012; Sufatinib; Sulanda; Sulfatinib - HUTCHMED

Latest Information Update: 14 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hutchison MediPharma
  • Developer Fujian Cancer Hospital; Hutchison MediPharma; HUTCHMED
  • Class Antineoplastics; Indoles; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Macrophage colony-stimulating factor receptor antagonists; Type 1 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neuroendocrine tumours
  • Phase II/III Biliary cancer; Pancreatic cancer
  • Phase II Colorectal cancer; Small cell lung cancer; Solid tumours; Thyroid cancer
  • Phase I/II Soft tissue sarcoma
  • Preclinical Non-small cell lung cancer

Most Recent Events

  • 25 Jul 2025 Hutchmed terminate a phase II trial in Neuroendocrine tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, France, Italy, Germany, Spain, Norway and the UK (PO) (NCT04579679)
  • 31 May 2024 Efficacy and adverse events data from a phase II trial in Small cell lung cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 08 May 2024 Phase-II/III clinical trials in Pancreatic cancer (Metastatic disease, Combination therapy, Late-stage disease, First-line therapy) in China (PO) (NCT06361888)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top